PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CANCER COMPRISING ALLOGENIC LYMPHOCYTES OR THEIR COMBINATION WITH A T-CELL ACTIVATOR

摘要

The use of allogenic lymphocytes in the manufacture of a medicament for the treatment of a human cancer patient, substantially as described in the specification, said patient having undergone a malignant cell debulking procedure and having further undergone autologous stem cell transplantation incident to said debulking procedure, said patient being at risk for disease relapse due to a population of residueal malignant cells that may remain viable in said patient following said debulking procedure, said treatment comprising: (a) monitoring said patient until said patient is partially hematopoiesis recovered but is not fully immune-reconstituted; (b) administering to said patient allogenic lymphocytes in a regimen that causes a clinically significant graft-versus-malignant cell response or a mild graft-versus-host response; and (c) monitoring said patient for levels of malignant cells deriving from said population of residual malignant cells. 15 כ" ז בסיון התשס" א - May 20, 2001